Deal would further strengthen Watson-Actavis' Asian position
This article was originally published in Scrip
Any global merger between Watson Pharmaceuticals and Actavis would give the combined group a stronger position in the critical established and emerging markets of Asia, where the Swiss-based firm and more recently its US rival have been steadily building up their operations
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.